BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Bruna Maria Roesler, Sandra Cecília Botelho Costa, José Murilo Robilotta Zeitune. Eradication Treatment of Helicobacter pylori Infection: Its Importance and Possible Relationship in Preventing the Development of Gastric CancerISRN Gastroenterology 2012; 2012: 1 doi: 10.5402/2012/935410
2
E. M. F. Muri, T. G. Barros. Hydroxamic Acids2013; : 241 doi: 10.1007/978-3-642-38111-9_9
3
Hafez Fakheri, Zohreh Bari, Hossein Sardarian. A modified Bismuth-Containing Quadruple Therapy Including a Short Course of Furazolidone for Helicobacter pylori Eradication After Sequential Therapy FailureHelicobacter 2012; 17(4): 264 doi: 10.1111/j.1523-5378.2012.00946.x
4
Seng-Kee Chuah, Wei-Chen Tai, Chen-Hsiang Lee, Chih-Ming Liang, Tsung-Hui Hu. Quinolone-Containing Therapies in the Eradication ofHelicobacter pyloriBioMed Research International 2014; 2014: 1 doi: 10.1155/2014/151543
5
Sung Woo Jung, Sang Woo Lee. The antibacterial effect of fatty acids on <i>Helicobacter pylori</i> infectionThe Korean Journal of Internal Medicine 2015; 31(1): 30 doi: 10.3904/kjim.2016.31.1.30
6
R Ozgur Karaca, Said Kalkisim, Akif Altinbas, Serta Kilincalp, Ilhami Yuksel, Mustafa T Goktas, Umit Yasar, Atilla Bozkurt, Melih O Babaoglu. Effects of Genetic Polymorphisms of Cytochrome P450 Enzymes and MDR1 Transporter on Pantoprazole Metabolism andHelicobacter pyloriEradicationBasic & Clinical Pharmacology & Toxicology 2017; 120(2): 199 doi: 10.1111/bcpt.12667
7
Seng-Kee Chuah, Ping-I Hsu, Kuo-Chin Chang, Yi-Chun Chiu, Keng-Liang Wu, Yeh-Pin Chou, Ming-Luen Hu, Wei-Chen Tai, King-Wah Chiu, Shue-Shian Chiou, Deng-Chyang Wu, Tsung-Hui Hu. Randomized Comparison of Two Non-Bismuth-Containing Second-line Rescue Therapies for Helicobacter pyloriHelicobacter 2012; 17(3): 216 doi: 10.1111/j.1523-5378.2012.00937.x
8
Mounia Lahbabi, Samia Alaoui, Karima El Rhazi, Mohammed El Abkari, Chakib Nejjari, Afaf Amarti, Bahia Bennani, Mustapha Mahmoud, Adil Ibrahimi, Dafr Allah Benajah. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: Result of the HPFEZ randomised studyClinics and Research in Hepatology and Gastroenterology 2013; 37(4): 416 doi: 10.1016/j.clinre.2012.10.002
9
Chao-Hung Kuo, Fu-Chen Kuo, Huang-Ming Hu, Chung-Jung Liu, Sophie S. W. Wang, Yen-Hsu Chen, Ming-Chia Hsieh, Ming-Feng Hou, Deng-Chyang Wu. The Optimal First-Line Therapy ofHelicobacter pyloriInfection in Year 2012Gastroenterology Research and Practice 2012; 2012: 1 doi: 10.1155/2012/168361
10
Jing Yu, Hui Ye, Jiang Li, Ning Li, Zong-ming Shi, Xue-zhi Zhang. The Antibacterial Activity of Mass Galla Chinesis et Camelliae Fermentata on Helicobacter pylori InfectionEvidence-Based Complementary and Alternative Medicine 2018; 2018: 1 doi: 10.1155/2018/1491732
11
Eva M. Kulik Kunz, Krystyna Lenkeit, Tuomas Waltimo, Roland Weiger, Clemens Walter. Combinatorial effects of amoxicillin and metronidazole on selected periodontal bacteria and whole plaque samplesArchives of Oral Biology 2014; 59(6): 608 doi: 10.1016/j.archoralbio.2014.03.007
12
Cheng-En Tsai, Chih-Ming Liang, Chen-Hsiang Lee, Yuan-Hung Kuo, Keng-Liang Wu, Yi-Chun Chiu, Wei-Chen Tai, Seng-Kee Chuah. First-line Helicobacter pylori eradication among patients with chronic liver diseases in TaiwanThe Kaohsiung Journal of Medical Sciences 2016; 32(8): 397 doi: 10.1016/j.kjms.2016.05.012
13
Brygida Kwiatkowska, Maria Maślińska. Macrolide Therapy in Chronic Inflammatory DiseasesMediators of Inflammation 2012; 2012: 1 doi: 10.1155/2012/636157
14
Chuan Wang, Zhifang Jia, Donghui Cao, Lili You, Meishan Jin, Xing Wu, Simin Wen, Xueyuan Cao, Jing Jiang, Valli De Re. Polymorphism of DNA Methyltransferase 3b and Association with Development and Prognosis in Gastric CancerPLOS ONE 2015; 10(8): e0134059 doi: 10.1371/journal.pone.0134059
15
Neus Muñoz, Jordi Sánchez-Delgado, Mireia Baylina, Sheila López-Góngora, Xavier Calvet. Prevalence of Helicobacter pylori resistance after failure of first-line therapy. A systematic reviewGastroenterología y Hepatología (English Edition) 2018; 41(10): 654 doi: 10.1016/j.gastre.2018.11.021
16
Wenming Wu, Yunsheng Yang, Gang Sun. Recent Insights into Antibiotic Resistance inHelicobacter pyloriEradicationGastroenterology Research and Practice 2012; 2012: 1 doi: 10.1155/2012/723183
17
Hyun Chul Lim, Yong Jae Lee, Byoungrak An, Seung Woo Lee, Yong Chan Lee, Byung Soo Moon. Rifabutin-based High-dose Proton-pump Inhibitor and Amoxicillin Triple Regimen as the Rescue treatment forHelicobacter pyloriHelicobacter 2014; 19(6): 455 doi: 10.1111/hel.12147
18
Tzung-Shiun Wu, Huang-Ming Hu, Fu-Chen Kuo, Chao-Hung Kuo. Eradication of Helicobacter pylori infectionThe Kaohsiung Journal of Medical Sciences 2014; 30(4): 167 doi: 10.1016/j.kjms.2013.11.003
19
Ekaterina Gavrish, Binu Shrestha, Chao Chen, Ida Lister, E. Jeffrey North, Lei Yang, Richard E. Lee, Angel Han, Bronwyn Williams, David Charnuska, Ken Coleman, Kim Lewis, Michael D. LaFleur. In VitroandIn VivoActivities of HPi1, a Selective Antimicrobial against Helicobacter pyloriAntimicrobial Agents and Chemotherapy 2014; 58(6): 3255 doi: 10.1128/AAC.02573-13
20
Peng Bai, Li Ya Zhou, Xiu Mei Xiao, Yang Luo, Yu Ding. Susceptibility ofHelicobacter pylorito antibiotics in Chinese patientsJournal of Digestive Diseases 2015; 16(8): 464 doi: 10.1111/1751-2980.12271
21
Angelo Zullo, Vincenzo De Francesco, Cesare Hassan, Lorenzo Ridola, Alessandro Repici, Vincenzo Bruzzese, Dino Vaira. Modified sequential therapy regimens for Helicobacter pylori eradication: A systematic reviewDigestive and Liver Disease 2013; 45(1): 18 doi: 10.1016/j.dld.2012.08.025
22
Hyung Min Noh, Su Jin Hong, Jae Pil Han, Kyung Woo Park, Yun Nah Lee, Tae Hee Lee, Bong Min Ko, Joon Seong Lee, Moon Sung Lee. Eradication Rate by Duration of Third-line Rescue Therapy with Levofloxacin afterHelicobacter pyloriTreatment Failure in Clinical PracticeThe Korean Journal of Gastroenterology 2016; 68(5): 260 doi: 10.4166/kjg.2016.68.5.260
23
Ping-I Hsu, Wen-Chi Chen, Feng-Woei Tsay, Chih-An Shih, Sung-Shuo Kao, Huay-Min Wang, Hsien-Chung Yu, Kwok-Hung Lai, Hui-Hwa Tseng, Nan-Jing Peng, Angela Chen, Chao-Hung Kuo, Deng-Chyang Wu. Ten-Day Quadruple Therapy Comprising Proton-Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin Achieves a High Eradication Rate forHelicobacter pyloriInfection after Failure of Sequential TherapyHelicobacter 2014; 19(1): 74 doi: 10.1111/hel.12085
24
Soohoon Kwon, Dong Ho Lee, Jae Bin Kang, Nayoung Kim, Young Soo Park, Cheol Min Shin, Hyuk Yoon, Yoon Jin Choi. The Efficacy of Bismuth-containing Quadruple Therapy after Moxifloxacin-based Sequential Therapy Failure inHelicobacter pyloriEradicationThe Korean Journal of Gastroenterology 2018; 71(4): 196 doi: 10.4166/kjg.2018.71.4.196
25
Sukhbir K Shahid. Novel anti-Helicobacter pylori therapiesPharmaceutical Patent Analyst 2014; 3(4): 411 doi: 10.4155/ppa.14.27
26
Fariborz Mansour-Ghanaei, Zahra Pedarpour, Afshin Shafaghi, Farahnaz Joukar. Clarithromycin versus Gemifloxacin in Quadruple Therapeutic Regimens for Helicobacter Pylori Infection EradicationMiddle East Journal of Digestive Diseases 2017; 9(2): 100 doi: 10.15171/mejdd.2017.58
27
Jun-Won Chung, Young Kul Jung, Yoon Jae Kim, Kwang Ahn Kwon, Jung Ho Kim, Jong Joon Lee, Sung Min Lee, Ki Baik Hahm, Sun Mi Lee, Jin Yong Jeong, Sung-Cheol Yun. Ten-day sequentialversustriple therapy forHelicobacter pylorieradication: A prospective, open-label, randomized trialJournal of Gastroenterology and Hepatology 2012; 27(11): 1675 doi: 10.1111/j.1440-1746.2012.07249.x
28
Li-Yuan Yu, Lu-Ning Sun, Xue-Hui Zhang, Yue-Qi Li, Lei Yu, Zi-Qing-Yun Yuan, Ling Meng, Hong-Wen Zhang, Yong-Qing Wang. A Review of the Novel Application and Potential Adverse Effects of Proton Pump InhibitorsAdvances in Therapy 2017; 34(5): 1070 doi: 10.1007/s12325-017-0532-9
29
F. Sierra, J.D. Forero, M. Rey. Ideal treatment for Helicobacter pylori: A systematic reviewRevista de Gastroenterología de México (English Edition) 2014; 79(1): 28 doi: 10.1016/j.rgmxen.2014.05.001
30
Neus Muñoz, Jordi Sánchez-Delgado, Mireia Baylina, Sheila López-Góngora, Xavier Calvet. Prevalencia de las resistencias de Helicobacter pylori tras el fracaso de una primera línea de tratamiento. Revisión sistemáticaGastroenterología y Hepatología 2018; 41(10): 654 doi: 10.1016/j.gastrohep.2018.06.014
31
Ben Wang, You-Hua Wang, Zhi-Fa Lv, Hui-Fang Xiong, Hui Wang, Yang Yang, Yong Xie. Review: Efficacy and Safety of Hybrid Therapy forHelicobacter pyloriInfection: A Systematic Review and Meta-analysisHelicobacter 2015; 20(2): 79 doi: 10.1111/hel.12180
32
Xuan Weng, Suresh Neethirajan, Adam Vogt. Single Cell Chemotactic Responses of Helicobacter pylori to Urea in a Microfluidic ChipApplied Sciences 2016; 6(5): 139 doi: 10.3390/app6050139
33
Acacia Lamb, Lin-Feng Chen. Role of theHelicobacter pylori-Induced inflammatory response in the development of gastric cancerJournal of Cellular Biochemistry 2013; 114(3): 491 doi: 10.1002/jcb.24389
34
Feng-Woei Tsay, Deng-Chyang Wu, Sung-Shuo Kao, Tzung-Jium Tsai, Kwok-Hung Lai, Jin-Shiung Cheng, Hoi-Hung Chan, Huay-Min Wang, Wei-Lun Tsai, Hui-Hwa Tseng, Nan-Jin Peng, Ping-I Hsu. Reverse Sequential Therapy Achieves a Similar Eradication Rate as Standard Sequential Therapy forHelicobacter pyloriEradication: A Randomized Controlled TrialHelicobacter 2015; 20(1): 71 doi: 10.1111/hel.12176
35
Katayoun Borhani, Ashraf Mohabati Mobarez, Ali Reza Khabiri, Mehrdad Behmanesh, Nima Khoramabadi. Inhibitory effects of rHP-NAP IgY against Helicobacter pylori attachment to AGS cell lineMicrobial Pathogenesis 2016; 97: 231 doi: 10.1016/j.micpath.2016.06.004
36
Jhen-Hong Wong, Kuo-Hao Ho, Sean Nam, Wen-Li Hsu, Chia-Hsien Lin, Che-Mai Chang, Jaw-Yuan Wang, Wei-Chiao Chang. Store-operated Ca2+ Entry Facilitates the Lipopolysaccharide-induced Cyclooxygenase-2 Expression in Gastric Cancer CellsScientific Reports 2017; 7(1) doi: 10.1038/s41598-017-12648-1
37
Maria Harmati, Edina Gyukity-Sebestyen, Gabriella Dobra, Gabriella Terhes, Edit Urban, Gabor Decsi, Neda Mimica-Dukić, Marija Lesjak, Nataša Simin, Bernadett Pap, Istvan B. Nemeth, Krisztina Buzas. Binary mixture ofSatureja hortensisandOriganum vulgaresubsp.hirtumessential oils: in vivo therapeutic efficiency againstHelicobacter pyloriinfectionHelicobacter 2017; 22(2): e12350 doi: 10.1111/hel.12350
38
Seng-Kee Chuah, Wei-Chen Tai, Pin-I Hsu, Deng-Chyang Wu, Keng-Liang Wu, Chung-Mou Kuo, Yi-Chun Chiu, Ming-Luen Hu, Yeh-Pin Chou, Yuan-Hung Kuo, Chih-Ming Liang, King-Wah Chiu, Tsung-Hui Hu. The Efficacy of Second-Line Anti-Helicobacter pyloriTherapy Using an Extended 14-Day Levofloxacin/Amoxicillin/Proton-Pump Inhibitor Treatment - A Pilot StudyHelicobacter 2012; 17(5): 374 doi: 10.1111/j.1523-5378.2012.00960.x
39
Jayaram Lakshmaiah Narayana, Han-Ning Huang, Chang-Jer Wu, Jyh-Yih Chen. Epinecidin-1 antimicrobial activity: In vitro membrane lysis and In vivo efficacy against Helicobacter pylori infection in a mouse modelBiomaterials 2015; 61: 41 doi: 10.1016/j.biomaterials.2015.05.014
40
Natalie Amar, Avi Peretz, Yoram Gerchman. A cheap, simple high throughput method for screening native Helicobacter pylori urease inhibitors using a recombinant Escherichia coli , its validation and demonstration of Pistacia atlantica methanolic extract effectivity and specificityJournal of Microbiological Methods 2017; 133: 40 doi: 10.1016/j.mimet.2016.11.022
41
Seng-Kee Chuah, Deng-Chyang Wu, Hidekazu Suzuki, Khean-Lee Goh, John Kao, Jian-Lin Ren. Peptic Ulcer Diseases: Genetics, Mechanism, and TherapiesBioMed Research International 2014; 2014: 1 doi: 10.1155/2014/898349
42
Mohammad Reza Esmaeili-Dooki, Hossein Shirdel, Mahmood Hajiahmadi. Eradication of Helicobacter pylori in Children by Triple Therapy Regimens of Amoxicillin, Omeprazole, and Clarithromycin or AzithromycinIranian Journal of Pediatrics 2015; 25(6) doi: 10.5812/ijp.2360
43
P. Nazari, R. Dowlatabadi-Bazaz, M. R. Mofid, M. R. Pourmand, N. E. Daryani, M. A. Faramarzi, Z. Sepehrizadeh, A. R. Shahverdi. The Antimicrobial Effects and Metabolomic Footprinting of Carboxyl-Capped Bismuth Nanoparticles Against Helicobacter pyloriApplied Biochemistry and Biotechnology 2014; 172(2): 570 doi: 10.1007/s12010-013-0571-x
44
Hideo Tanaka. Epidemiologic Studies in Cancer Prevention and ScreeningStatistics for Biology and Health 2013; 79: 65 doi: 10.1007/978-1-4614-5586-8_5
45
Te-Fu Lin, Ping-I Hsu. Second-line rescue treatment of <i>Helicobacter pylori</i> infection: Where are we now?World Journal of Gastroenterology 2018; 24(40): 4548-4553 doi: 10.3748/wjg.v24.i40.4548
46
Nuno Almeida, Maria Manuel Donato, José Manuel Romãozinho, Cristina Luxo, Olga Cardoso, Maria Augusta Cipriano, Carol Marinho, Alexandra Fernandes, Carlos Sofia. Correlation of Helicobacter pylori Genotypes with Gastric Histopathology in the Central Region of a South-European CountryDigestive Diseases and Sciences 2015; 60(1): 74 doi: 10.1007/s10620-014-3319-8
47
Shen-Shong Chang, Hsiao-Yun Hu. <italic>Helicobacter pylori</italic>: Effect of coexisting diseases and update on treatment regimensWorld Journal of Gastrointestinal Pharmacology and Therapeutics 2015; 6(4): 127-136 doi: 10.4292/wjgpt.v6.i4.127
48
Halil Rakici, Remzi Adnan Akdoğan, Recep Bedir, Aysegul Copur, Arif Yilmaz. Comparison of standard triple therapy, sequential therapy and moxifloxacin-based triple therapy forHelicobacter pyloriinfection: Patients' compliance and bacterial eradication ratesJournal of Digestive Diseases 2014; 15(9): 508 doi: 10.1111/1751-2980.12171
49
Lucinda J. Bessa, Rossella Grande, Donato DI Iorio, Mara DI Giulio, Emanuela DI Campli, Luigina Cellini. Helicobacter pylorifree-living and biofilm modes of growth: behavior in response to different culture mediaAPMIS 2013; 121(6): 549 doi: 10.1111/apm.12020
50
Bekir Kocazeybek, Hrisi Bahar Tokman. Prevalence of Primary Antimicrobial Resistance ofH. pyloriin Turkey: A Systematic ReviewHelicobacter 2016; 21(4): 251 doi: 10.1111/hel.12272
51
JING JIANG, DONG-HUI CAO, TETSUYA TSUKAMOTO, GUO-QING WANG, ZHI-FANG JIA, JIAN SUO, XUE-YUAN CAO. Anticancer effects of 4-vinyl-2,6-dimethoxyphenol (canolol) against SGC-7901 human gastric carcinoma cellsOncology Letters 2013; 5(5): 1562 doi: 10.3892/ol.2013.1230
52
Wei-Chen Tai, Chien-Hua Chiu, Chih-Ming Liang, Kuo-Chin Chang, Chung-Mou Kuo, Yi-Chun Chiu, Keng-Liang Wu, Ming-Luen Hu, Yeh-Pin Chou, Shue-Shian Chiou, King-Wah Chiu, Chung-Huang Kuo, Tsung-Hui Hu, Ming-Tsung Lin, Seng-Kee Chuah. Ten-Day versus 14-Day Levofloxacin-Containing Triple Therapy for Second-Line Anti-Helicobacter pyloriEradication in TaiwanGastroenterology Research and Practice 2013; 2013: 1 doi: 10.1155/2013/932478
53
Reza Ghotaslou, Morteza Milani, Mohammad Taghi Akhi, Mohammad Saeid Hejazi, Mohammad Reza Nahaei, Alka Hasani, Yaeghob Sharifi. Relationship Between Drug Resistance and cagA Gene in Helicobacter pyloriJundishapur Journal of Microbiology 2013; 6(10) doi: 10.5812/jjm.8480
54
Nuno Almeida, José M. Romãozinho, Maria M. Donato, Cristina Luxo, Olga Cardoso, Maria A. Cipriano, Carol Marinho, Carlos Sofia. Triple Therapy with High-Dose Proton-Pump Inhibitor, Amoxicillin, and Doxycycline Is Useless forHelicobacter pyloriEradication: A Proof-of-Concept StudyHelicobacter 2014; 19(2): 90 doi: 10.1111/hel.12106
55
Ping-I Hsu, Nan-Jing Peng. H. pyloriEradication TherapyGastroenterology Research and Practice 2013; 2013: 1 doi: 10.1155/2013/935635
56
Xue-Yuan Cao, Zhi-Fang Jia, Dong-Hui Cao, Fei Kong, Mei-Shan Jin, Jian Suo, Jing Jiang. DNMT3a rs1550117 Polymorphism Association with Increased Risk of Helicobacter pylori InfectionAsian Pacific Journal of Cancer Prevention 2013; 14(10): 5713 doi: 10.7314/APJCP.2013.14.10.5713
57
M. Gasparetto, M. Pescarin, G. Guariso. Helicobacter pylori Eradication Therapy: Current AvailabilitiesISRN Gastroenterology 2012; 2012: 1 doi: 10.5402/2012/186734
58
Angelo Zullo, Cesare Hassan, Lorenzo Ridola, Vincenzo De Francesco, Dino Vaira. Standard triple and sequential therapies for Helicobacter pylori eradication: An updateEuropean Journal of Internal Medicine 2013; 24(1): 16 doi: 10.1016/j.ejim.2012.07.006
59
Jun-Won Chung, Minsu Ha, Sung-Cheol Yun, Jung Ho Kim, Jong Jun Lee, Yoon Jae Kim, Kyoung Oh Kim, Kwang An Kwon, Dong Kyun Park, Dong Ho Lee. Meta-analysis: Sequential Therapy Is Superior to Conventional Therapy forHelicobacter pyloriInfection in KoreaThe Korean Journal of Gastroenterology 2013; 62(5): 267 doi: 10.4166/kjg.2013.62.5.267
60
Hyasinta Jaka, Andreas Mueller, Christa Kasang, Stephen E. Mshana. Predictors of triple therapy treatment failure among H. pylori infected patients attending at a tertiary hospital in Northwest Tanzania: a prospective studyBMC Infectious Diseases 2019; 19(1) doi: 10.1186/s12879-019-4085-1
61
Shu-Ping Xiao, Min Gu, Guo-Xin Zhang. Is levofloxacin-based triple therapy an alternative for first-line eradication ofHelicobacter pylori? A systematic review and meta-analysisScandinavian Journal of Gastroenterology 2014; 49(5): 528 doi: 10.3109/00365521.2014.887765
62
Deng-Chyang Wu, Chao-Hung Kuo, Feng-Woei Tsay, Wen-Hung Hsu, Angela Chen, Ping-I Hsu. A Pilot Randomized Controlled Study of Dexlansoprazole MR-Based Triple Therapy for Helicobacter Pylori InfectionMedicine 2016; 95(11): e2698 doi: 10.1097/MD.0000000000002698
63
Carlo‐Federico Zambon, Daniela Basso, Michela Pelloso, Alberto Tessari, Mario Plebani. Human Emerging and Re‐emerging Infections2015; : 607 doi: 10.1002/9781118644843.ch33
64
Olga Cardoso, Maria Manuel Donato, Cristina Luxo, Nuno Almeida, Joana Liberal, Artur Figueirinha, Maria Teresa Batista. Anti- Helicobacter pylori potential of Agrimonia eupatoria L. and Fragaria vescaJournal of Functional Foods 2018; 44: 299 doi: 10.1016/j.jff.2018.03.027
65
Morris O. Makobongo, Leo Einck, Richard M. Peek, D. Scott Merrell, Asad U Khan. In Vitro Characterization of the Anti-Bacterial Activity of SQ109 against Helicobacter pyloriPLoS ONE 2013; 8(7): e68917 doi: 10.1371/journal.pone.0068917
66
Stanisław Ferenc, Jan Gnus, Magdalena Kościelna, Małgorzata Kinda, Andriy Yarka, Luke Stewart, Wojciech Witkiewicz. High antibiotic resistance ofHelicobacter pyloriand its effect on tailored and empiric eradication of the organism in Lower Silesia, PolandHelicobacter 2017; 22(2): e12365 doi: 10.1111/hel.12365
67
Jiunn-Wei Wang, Chien-Ning Hsu, Wei-Chen Tai, Ming-Kun Ku, Tsung-Hsing Hung, Kuo-Lun Tseng, Lan-Ting Yuan, Seng-Howe Nguang, Chih-Ming Liang, Shih-Cheng Yang, Cheng-Kun Wu, Pin-I Hsu, Deng-Chyang Wu, Seng-Kee Chuah, Giuseppe Remuzzi. The Association of Helicobacter pylori Eradication with the Occurrences of Chronic Kidney Diseases in Patients with Peptic Ulcer DiseasesPLOS ONE 2016; 11(10): e0164824 doi: 10.1371/journal.pone.0164824
68
Amin Talebi Bezmin Abadi. Therapy ofHelicobacter pylori: Present Medley and Future ProspectiveBioMed Research International 2014; 2014: 1 doi: 10.1155/2014/124607
69
F. Sierra, J.D. Forero, M. Rey. Tratamiento ideal del Helicobacter pylori: una revisión sistemáticaRevista de Gastroenterología de México 2014; 79(1): 28 doi: 10.1016/j.rgmx.2013.03.003
70
Wei-Chen Tai, Chen-Hsiang Lee, Shue-Shian Chiou, Chung-Mou Kuo, Chung-Huang Kuo, Chih-Ming Liang, Lung-Sheng Lu, Chien-Hua Chiu, Keng-Liang Wu, Yi-Chun Chiu, Tsung-Hui Hu, Seng-Kee Chuah, Ivo G. Boneca. The Clinical and Bacteriological Factors for Optimal Levofloxacin-Containing Triple Therapy in Second-Line Helicobacter pylori EradicationPLoS ONE 2014; 9(8): e105822 doi: 10.1371/journal.pone.0105822
71
Pramodini B. Kale-Pradhan, Anela Mihaescu, Sheila M. Wilhelm. Fluoroquinolone Sequential Therapy forHelicobacter pylori: A Meta-analysisPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 2015; 35(8): 719 doi: 10.1002/phar.1614
72
Mireia Baylina, Neus Muñoz, Jordi Sánchez‐Delgado, Sheila López‐Góngora, Xavier Calvet, Ignasi Puig. Systematic review: Would susceptibility‐guided treatment achieve acceptable cure rates for second‐line Helicobacter pylori therapy as currently practiced? Helicobacter 2019; 24(3): e12584 doi: 10.1111/hel.12584
73
Neus Muñoz, Jordi Sánchez-Delgado, Mireia Baylina, Ignasi Puig, Sheila López-Góngora, David Suarez, Xavier Calvet. Systematic review, meta-analysis, and meta-regression: Successful second-line treatment for Helicobacter pylori Helicobacter 2018; 23(3): e12488 doi: 10.1111/hel.12488
74
Seng-Kee Chuah, Chih-Ming Liang, Chen-Hsiang Lee, Shue-Shian Chiou, Yi-Chun Chiu, Ming-Luen Hu, Keng-Liang Wu, Lung-Sheng Lu, Yeh-Pin Chou, Kuo-Chin Chang, Chung-Huang Kuo, Chung-Mou Kuo, Tsung-Hui Hu, Wei-Chen Tai. A Randomized Control Trial Comparing 2 Levofloxacin-Containing Second-Line Therapies for Helicobacter pylori EradicationMedicine 2016; 95(19): e3586 doi: 10.1097/MD.0000000000003586
75
Ping-I Hsu, Sung-Shuo Kao, Deng-Chyang Wu, Wen-Chi Chen, Nan-Jing Peng, Hsien-Chung Yu, Huay-Min Wang, Kwok-Hung Lai, Jin-Shiung Cheng, Angela Chen, Seng-Kee Chuah, Feng-Woei Tsay. A Randomized Controlled Study Comparing Reverse Hybrid Therapy and Standard Triple Therapy for Helicobacter pylori InfectionMedicine 2015; 94(48): e2104 doi: 10.1097/MD.0000000000002104
76
Thomas A Keating. Resistance mechanism to an uncompetitive inhibitor of a single-substrate, single-product enzyme: a study ofHelicobacter pyloriglutamate racemaseFuture Medicinal Chemistry 2013; 5(11): 1203 doi: 10.4155/fmc.13.94
77
Antonio Rollan, Juan Pablo Arab, M Constanza Camargo, Roberto Candia, Paul Harris, Catterina Ferreccio, Charles S Rabkin, Juan Crist&oacute;bal Gana, Pablo Cort&eacute;s, Rolando Herrero, Luisa Dur&aacute;n, Apolinaria Garc&iacute;a, Claudio Toledo, Alberto Espino, Nicole Lustig, Alberto Sarfatis, Catalina Figueroa, Javier Torres, Arnoldo Riquelme. Management of <italic>Helicobacter pylori</italic> infection in Latin America: A Delphi technique-based consensusWorld Journal of Gastroenterology 2014; 20(31): 10969-10983 doi: 10.3748/wjg.v20.i31.10969
78
Joshua P. Owings, Nina N. McNair, Yiu Fung Mui, Tomas N. Gustafsson, Arne Holmgren, Maria Contel, Joanna B. Goldberg, Jan R. Mead, Lígia Saraiva. Auranofin andN-heterocyclic carbene gold-analogs are potent inhibitors of the bacteriaHelicobacter pyloriFEMS Microbiology Letters 2016; 363(14): fnw148 doi: 10.1093/femsle/fnw148
79
Sotirios D. Georgopoulos, Vasilios Papastergiou, Stylianos Karatapanis. Helicobacter  pyloriEradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved EfficacyGastroenterology Research and Practice 2012; 2012: 1 doi: 10.1155/2012/757926
80
Amin Talebi Bezmin Abadi. Helicobacter pylori treatment: New perspectives using current experienceJournal of Global Antimicrobial Resistance 2017; 8: 123 doi: 10.1016/j.jgar.2016.11.008
81
Ping-I Hsu, Pei-Chin Lin, David Y Graham. Hybrid therapy for <italic>Helicobacter pylori</italic> infection: A systemic review and meta-analysisWorld Journal of Gastroenterology 2015; 21(45): 12954-12962 doi: 10.3748/wjg.v21.i45.12954
82
Maliheh Safavi, Mohammadreza Shams-Ardakani, Alireza Foroumadi. Medicinal plants in the treatment ofHelicobacter pyloriinfectionsPharmaceutical Biology 2015; 53(7): 939 doi: 10.3109/13880209.2014.952837
83
Soohoon Kwon, Dong Ho Lee, Jae Bin Kang, Nayoung Kim, Young Soo Park, Cheol Min Shin, Hyuk Yoon, Yoon Jin Choi. The Efficacy of Moxifloxacin-containing Triple Therapy after Hybrid Therapy Failure in Helicobacter pylori EradicationThe Korean Journal of Gastroenterology 2017; 70(2): 72 doi: 10.4166/kjg.2017.70.2.72
84
I. Thung, H. Aramin, V. Vavinskaya, S. Gupta, J. Y. Park, S. E. Crowe, M. A. Valasek. Review article: the global emergence ofHelicobacter pyloriantibiotic resistanceAlimentary Pharmacology & Therapeutics 2016; 43(4): 514 doi: 10.1111/apt.13497
85
Chih-Ming Liang, Chien-Hua Chiu, Hsing-Ming Wang, Wei-Chen Tai, Chih-Chien Yao, Cheng-En Tsai, Chung-Mou Kuo, Yi-Chun Chiu, Keng-Liang Wu, Chen-Hsiang Lee, Kai-Lung Tsai, Chih-Fang Huang, Seng-Kee Chuah. First-Line Helicobacter pylori Eradication in Patients with Chronic Kidney Diseases in TaiwanBioMed Research International 2017; 2017: 1 doi: 10.1155/2017/3762194
86
F. Sierra, J. D. Forero, M. Rey, M. L. Botero, A. Cárdenas. Pilot study: miscellaneous therapy is highly successful forHelicobacter pylorieradicationAlimentary Pharmacology & Therapeutics 2013; 37(12): 1165 doi: 10.1111/apt.12329
87
Nuno Almeida, Maria Manuel Donato, José Manuel Romãozinho, Cristina Luxo, Olga Cardoso, Maria Augusta Cipriano, Carol Marinho, Alexandra Fernandes, Carlos Calhau, Carlos Sofia. Beyond Maastricht IV: are standard empiric triple therapies for Helicobacter pylori still useful in a South-European country?BMC Gastroenterology 2015; 15(1) doi: 10.1186/s12876-015-0245-y
88
Jihee Sung, Nayoung Kim, Yo Han Park, Young Jae Hwang, Soohoon Kwon, Gyeongjae Na, Joon Young Choi, Jae Bin Kang, Hye Rang Kim, Jin-Wook Kim, Dong Ho Lee. Rifabutin-based Fourth and Fifth-line Rescue Therapy in Patients with forHelicobacter pyloriEradication FailureThe Korean Journal of Gastroenterology 2017; 69(2): 109 doi: 10.4166/kjg.2017.69.2.109
89
Yi-Chun Chiu, Wei-Chen Tai, Seng-Kee Chuah, Ping-I Hsu, Deng-Chyang Wu, Keng-Liang Wu, Chao-Cheng Huang, Ji-Chen Ho, Johannes Ring, Wen-Chieh Chen. The Clinical Correlations ofHelicobacter pyloriVirulence Factors and Chronic Spontaneous UrticariaGastroenterology Research and Practice 2013; 2013: 1 doi: 10.1155/2013/436727